Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
Status:
Withdrawn
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
After successful screening the cases of cirrhosis of liver irrespective of the etiology who
have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will
be recorded and the patient will be randomized into either interventional (acenocoumarol) or
placebo group along with first five days of subcutaneous Low Molecular Weight Heparin inj.
Enoxaparin in the interventional arm and placebo injection in the control arm. Every 3
monthly the Doppler screening for recanalization of portal vein thrombus will be done with
monitoring of International Normalized Ratio (INR)with target INR 2-3. Both the groups will
receive the therapy for one year irrespective of the Doppler findings in relation to portal
vein thrombus re-canalization.Then one year drug free monitoring will be done in both the
groups as per the primary or secondary outcome. .